ABT-SLV187

( DrugBank: - / KEGG DRUG: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
6	パーキンソン病	4

6. パーキンソン病

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

trials per page:

Showing 1 to 4 of 4 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02082249 (ClinicalTrials.gov)	March 10, 2014	14/2/2014	An Extension Study to Assess the Safety, Tolerability and Efficacy of ABT-SLV187in Subjects With Adv ...	An Open-Label Three-Part Extension Study Assessing Safety, Tolerability and Efficacy of ABT-SLV187in ...	Advanced Parkinson's Disease	Drug: ABT-SLV187	AbbVie	NULL	Completed	30 Years	99 Years	All	30	Phase 3	Japan;Korea, Republic of;Taiwan
2	NCT01960842 (ClinicalTrials.gov)	October 2013	9/10/2013	A Study to Assess the Efficacy, Safety and Tolerability of ABT-SLV187Monotherapy in Subjects With Ad ...	An Open-Label, Single-Arm, Baseline-Controlled, Multicenter Study to Evaluate the Efficacy, Safety a ...	Advanced Parkinson's Disease	Drug: Levodopa-carbidopa intestinal gel;Device: CADD-Legacy® 1400 ambulatory infusion pump;Device: P ...	AbbVie	NULL	Completed	30 Years	N/A	All	31	Phase 3	Japan;Korea, Republic of;Taiwan
3	NCT01479127 (ClinicalTrials.gov)	October 2011	26/9/2011	Study of Safety, Tolerability, Pharmacokinetics, and Efficacy of ABT-SLV187in Subjects With Advanced ...	An Open-Label, Single-Arm, Baseline-Controlled, Multicenter Study to Explore the Safety, Tolerabilit ...	Advanced Parkinson's Disease	Drug: ABT-SLV187;Drug: Oral Levodopa/Carbidopa;Device: Infusion Pump: CADD-Legacy® 1400 Pump;Device: ...	AbbVie (prior sponsor, Abbott)	Abbott Japan Co.,Ltd	Completed	30 Years	99 Years	All	8	Phase 2	Japan
4	JPRN-JapicCTI-111699		22/11/2011	Study of Safety, Tolerability, Pharmacokinetics, and Efficacy of ABT-SLV187in Subjects With Advanced ...	An Open-Label, Single-Arm, Baseline-Controlled, Multicenter Study to Explore the Safety, Tolerabilit ...	Advanced Parkinson's disease	Intervention name : ABT-SLV187 Dosage And administration of the intervention : Usually 2-6 ml/hour (4 ...	Abbott Japan Co., Ltd.	NULL		30		BOTH	8	Phase 2	NULL

First Previous1Next Last